Spark Therapeutics (ONCE) Misses Q3 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Spark Therapeutics Reports Third Quarter 2015 Financial Results and Recent Business Highlights
November 4, 2015 8:01 AM ESTReported positive top-line results from pivotal Phase 3 trial of SPK-RPE65 for genetic blinding conditionsDurability of effect of SPK-RPE65 reported at three years with observation ongoingContinued progression and expansion of pipeline and operations
PHILADELPHIA, Nov. 04, 2015 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE) today announced financial results for the quarter ended September 30, 2015 and updated investors on its operational progress.
Last month we released positive Phase 3 data from... More
